Literature DB >> 12653848

Altered CD8+ T cell responses to selected Epstein-Barr virus immunodominant epitopes in patients with multiple sclerosis.

P Höllsberg1, H J Hansen, S Haahr.   

Abstract

An increased frequency of antiviral CD8+ T cells is seen in chronic viral infections. During herpes virus infections the expanded CD8+ T cells are thought to control the reactivation of the latent infection. Because multiple sclerosis (MS), a presumed autoimmune disease of the central nervous system, has been associated with a late Epstein-Barr virus (EBV) infection, we wished to examine whether the CD8+ T cell response to EBV epitopes differed between MS patients and healthy controls. Here we report an increased frequency of CD8+ T cells responding to EBV epitopes from nuclear antigen 3 A (HLA-A2/CLG) and latent membrane protein 2 (HLA-B7/RPP) in MS patients. Noticeably, the altered CD8+ T cell response occurred to some but not all EBV epitopes and did not reach the high level seen during acute infection. The responses towards two immunodominant epitopes from human cytomegalovirus (HCMV) were similar in MS patients and normal controls. Together, our data demonstrate the presence of an increased frequency of CD8+ T cells reacting with two epitopes from EBV in patients with MS. The altered response to only two of the tested EBV epitopes would be consistent with the presence of cross-reactive epitopes.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12653848      PMCID: PMC1808679          DOI: 10.1046/j.1365-2249.2003.02114.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  41 in total

1.  Longitudinal dynamics of antigen-specific CD8+ cytotoxic T lymphocytes following primary Epstein-Barr virus infection.

Authors:  M Bharadwaj; S R Burrows; J M Burrows; D J Moss; M Catalina; R Khanna
Journal:  Blood       Date:  2001-10-15       Impact factor: 22.113

2.  Epstein-Barr virus antibodies and risk of multiple sclerosis: a prospective study.

Authors:  A Ascherio; K L Munger; E T Lennette; D Spiegelman; M A Hernán; M J Olek; S E Hankinson; D J Hunter
Journal:  JAMA       Date:  2001-12-26       Impact factor: 56.272

3.  Cross-reactivity between hepatitis C virus and Influenza A virus determinant-specific cytotoxic T cells.

Authors:  H Wedemeyer; E Mizukoshi; A R Davis; J R Bennink; B Rehermann
Journal:  J Virol       Date:  2001-12       Impact factor: 5.103

4.  Association between clinical disease activity and Epstein-Barr virus reactivation in MS.

Authors:  K Wandinger; W Jabs; A Siekhaus; S Bubel; P Trillenberg; H Wagner; K Wessel; H Kirchner; H Hennig
Journal:  Neurology       Date:  2000-07-25       Impact factor: 9.910

5.  CD4+CD25high regulatory cells in human peripheral blood.

Authors:  C Baecher-Allan; J A Brown; G J Freeman; D A Hafler
Journal:  J Immunol       Date:  2001-08-01       Impact factor: 5.422

6.  Differential evolution and stability of epitope-specific CD8(+) T cell responses in EBV infection.

Authors:  M D Catalina; J L Sullivan; K R Bak; K Luzuriaga
Journal:  J Immunol       Date:  2001-10-15       Impact factor: 5.422

7.  Identification of three HLA-A*0201-restricted cytotoxic T cell epitopes in the cytomegalovirus protein pp65 that are conserved between eight strains of the virus.

Authors:  A Solache; C L Morgan; A I Dodi; C Morte; I Scott; C Baboonian; B Zal; J Goldman; J E Grundy; J A Madrigal
Journal:  J Immunol       Date:  1999-11-15       Impact factor: 5.422

8.  A randomized, double-blind, placebo-controlled MRI study of anti-herpes virus therapy in MS.

Authors:  E Bech; J Lycke; P Gadeberg; H J Hansen; C Malmeström; O Andersen; T Christensen; S Ekholm; S Haahr; P Höllsberg; T Bergström; B Svennerholm; J Jakobsen
Journal:  Neurology       Date:  2002-01-08       Impact factor: 9.910

9.  Changing patterns of dominant TCR usage with maturation of an EBV-specific cytotoxic T cell response.

Authors:  N E Annels; M F Callan; L Tan; A B Rickinson
Journal:  J Immunol       Date:  2000-11-01       Impact factor: 5.422

Review 10.  Role of cytotoxic T lymphocytes in Epstein-Barr virus-associated diseases.

Authors:  R Khanna; S R Burrows
Journal:  Annu Rev Microbiol       Date:  2000       Impact factor: 15.500

View more
  28 in total

Review 1.  99th Dahlem conference on infection, inflammation and chronic inflammatory disorders: Epstein-Barr virus and multiple sclerosis: epidemiological evidence.

Authors:  A Ascherio; K L Munger
Journal:  Clin Exp Immunol       Date:  2010-04       Impact factor: 4.330

2.  Cytomegalovirus and multiple sclerosis risk.

Authors:  Julia Pakpoor; Jina Pakpoor; Giulio Disanto; Gavin Giovannoni; Sreeram V Ramagopalan
Journal:  J Neurol       Date:  2013-04-16       Impact factor: 4.849

Review 3.  Epstein-barr virus infection and multiple sclerosis: a review.

Authors:  Alberto Ascherio; Kassandra L Munger
Journal:  J Neuroimmune Pharmacol       Date:  2010-04-06       Impact factor: 4.147

4.  Epstein-Barr virus and disease activity in multiple sclerosis.

Authors:  D Buljevac; G J J van Doornum; H Z Flach; J Groen; A D M E Osterhaus; W Hop; P A van Doorn; F G A van der Meché; R Q Hintzen
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-10       Impact factor: 10.154

5.  Mice expressing human ERAP1 variants associated with ankylosing spondylitis have altered T-cell repertoires and NK cell functions, as well as increased in utero and perinatal mortality.

Authors:  David P W Rastall; Fadel S Alyaquob; Patrick O'Connell; Yuliya Pepelyayeva; Douglas Peters; Sarah Godbehere-Roosa; Cristiane Pereira-Hicks; Yasser A Aldhamen; Andrea Amalfitano
Journal:  Int Immunol       Date:  2017-06-01       Impact factor: 4.823

6.  Anti-Epstein-Barr virus antibodies as serological markers of multiple sclerosis: a prospective study among United States military personnel.

Authors:  K L Munger; L I Levin; E J O'Reilly; K I Falk; A Ascherio
Journal:  Mult Scler       Date:  2011-06-17       Impact factor: 6.312

7.  Epstein-Barr virus infection is not a characteristic feature of multiple sclerosis brain.

Authors:  Simon N Willis; Christine Stadelmann; Scott J Rodig; Tyler Caron; Stefan Gattenloehner; Scott S Mallozzi; Jill E Roughan; Stefany E Almendinger; Megan M Blewett; Wolfgang Brück; David A Hafler; Kevin C O'Connor
Journal:  Brain       Date:  2009-12       Impact factor: 13.501

8.  The Ankylosing Spondylitis-associated HLA-B*2705 presents a B*0702-restricted EBV epitope and sustains the clonal amplification of cytotoxic T cells in patients.

Authors:  Valentina Tedeschi; Carolina Vitulano; Alberto Cauli; Fabiana Paladini; Matteo Piga; Alessandro Mathieu; Rosa Sorrentino; Maria Teresa Fiorillo
Journal:  Mol Med       Date:  2016-05-18       Impact factor: 6.354

9.  Decreased T cell reactivity to Epstein-Barr virus infected lymphoblastoid cell lines in multiple sclerosis.

Authors:  M P Pender; P A Csurhes; A Lenarczyk; C M M Pfluger; S R Burrows
Journal:  J Neurol Neurosurg Psychiatry       Date:  2008-11-17       Impact factor: 10.154

Review 10.  Is the risk of multiple sclerosis related to the 'biography' of the immune system?

Authors:  Bernd Krone; Frank Oeffner; John M Grange
Journal:  J Neurol       Date:  2009-03-01       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.